Sign up Australia
Proactive Investors - Run By Investors For Investors

Analysts upbeat on Pressure BioSciences

Analysts are upbeat on medical device firm Pressure BioSciences (OTCQB: PBIO), which generated “record” results in the first half and has momentum expected to continue.
Analysts upbeat on Pressure BioSciences
Pressure Biosciences is a medical device firm...

Analysts are upbeat on medical device firm Pressure BioSciences (OTCQB: PBIO), which generated “record” results in the first half, and whose momentum is expected to continue.

The group develops proprietary laboratory instrumentation  based on Pressure Cycling Technology (PCT) target what it estimates is a $6bn market opportunity providing tools to 80,000 research labs worldwide.

Seethru Equity notes that the firm has made tremendous strides this year by improving its balance sheet and generating strong growth.

Revenues in the first half were $0.85mln -  up 20% from a year ago.

"PBIO expects to eclipse $0.5mn in revenue in 3Q15, which would be a considerable milestone for the company as its annual run rate would surpass $2mn," it said.

"Meanwhile, PBIO has made substantial progress cleaning up its balance sheet. Since the close of 2Q15, the company has raised $3.28mn in two tranches of a $5mn private placement, which we believe will close in coming weeks."

It has price target of $1.57 on the stock and says it see the firm as an 'attractive, speculative' growth company.

"If achieved, the target represents potential upside of 554.2% from the recent price of $0.24," added Seethru Equity.

Meanwhile, Zacks Research said it continued to be bullish on the hares.

It has lifted its rating on the shares to 'buy' from 'hold' and has a 12 month target price of $2.50

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use